SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-061543
Filing Date
2021-11-23
Accepted
2021-11-23 15:15:54
Documents
79
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_allarity.htm   iXBRL 10-Q 851438
2 CERTIFICATION f10q0921ex31-1_allarity.htm EX-31.1 12260
3 CERTIFICATION f10q0921ex31-2_allarity.htm EX-31.2 12321
4 CERTIFICATION f10q0921ex32-1_allarity.htm EX-32.1 5125
5 CERTIFICATION f10q0921ex32-2_allarity.htm EX-32.2 5119
  Complete submission text file 0001213900-21-061543.txt   5118442

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE allr-20210930.xsd EX-101.SCH 74171
7 XBRL CALCULATION FILE allr-20210930_cal.xml EX-101.CAL 32900
8 XBRL DEFINITION FILE allr-20210930_def.xml EX-101.DEF 246694
9 XBRL LABEL FILE allr-20210930_lab.xml EX-101.LAB 534785
10 XBRL PRESENTATION FILE allr-20210930_pre.xml EX-101.PRE 262452
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_allarity_htm.xml XML 645871
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-258968 | Film No.: 211437930
SIC: 2834 Pharmaceutical Preparations